Search
Menu
Home
HTB
2010
December
HTB
December 2010
Contents
Editorial
Volume 11 Number 11/12 November/December 2010
Conference reports
10th International Congress on Drug Therapy in HIV Infection, 7-11 November 2010, Glasgow
Virological findings from the SARA trial ofboosted protease inhibitor monotherapy
Nevirapine exposure was not associated with hypersensitivity in patients from Malawi
Estimating the number of people in a country or region with HIV who are undiagnosed and in need of ART
Highpreterm delivery rates associated with initiation of HAART during pregnancy at a London clinic
Minority M184V variants detected in women after receiving 3TC/FTC and LPV/r-containing regimens in pregnancy
The Antiretroviral Pregnancy Registry reports no increased rate of birth defects with atazanavir exposure
Pharmacokinetics of lopinavir/ritonavir incombination with rifampicin based TB treatment in children
Efavirenz versus nevirapine based first linetreatment in a South African cohort
GSK572: 24-week results in treatment-naive and raltegravir-experienced patients
Consensus guidelines recommend routine use of genotypic tropism testing: new focus on maraviroc as a switching option (2010)
UK studies on bone health: increasedfracture rates reported in HIV-positive people
Muscle weakness or pain analysed as possible raltegravir side effect
Adding maraviroc does not boost CD4s inrandomised trial
Switch to twice-daily unboosted atazanavir outdoes switch to once-daily dose
Small but higher rates of AIDS and non-AIDS complications with uncontrolled HIV despite CD4s over 350
12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, 4-6 November 2010, London
Bio-Alcamid associated with unacceptable risk of complications: no longer recommended as a treatment for facial lipoatrophy
First International Workshop on HIV and Ageing, 4-5 October 2010, Baltimore
T-cell senescence linked to KS in peoplewith good HIV control
Higher risk of potential drug-drug interactions in HIV patients over 60
Age raises fracture risk more in HIV-positive people
Antiretrovirals
Once-daily raltegravir fails to demonstrate non-inferiority compared to twice-dailydosing in phase 3 treatment naive study
FDA safety updates to antiretroviral labels
Update to US saquinavir label
Treatment access
Shortfall in funding for the Global Fund
FDA approval of generic ARVs
Europe! HANDS OFF OUR MEDICINE
DNP+ president uses 5ml of blood to meet Carla Bruni-Sarkozy
Medicines Patent Pool: first research funder announced
Paediatric care
Initiating nevirapine with fixed dose combination mini-pills in Zambia
Side effects
FDA approves tesamorelin for reduction of central fat accumulation
HIV prevention and transmission
Pre-exposure prophylaxis (PrEP) with tenofovir/FTC reduces sexual transmission of HIV between men at high risk: results from the iPrEx study
Basic science and immunology
Berlin man remains free of detectable HIV 3.5 years after CCR5-negative stem celltransplant
Natural immunity to HIV infection
Scant embers of infection can reignite viralreplication
Evidence for sporadic low-level HIV replication on ART
Plumbing HIV pathogenesis in the gut
Genetic analyses reveal key mechanism of HIV control
BHIVA news
HIV: an agenda for action
On the web
Conference reports and online abstracts
Online journal access
Community resources and publications
PDFs
Volume 11 Number 11/12 November/December 2010 PDF
HTB RSS
Current issues
October 2024
September 2024
August 2024
Back issues
Special report
Major update of UK PrEP guidelines online for public consultation
1 October 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage